Lipid nanoparticles for targeted delivery of nucleic acids, and their preparation and application methods
By designing lipid nanoparticles containing an outer lipid membrane and a core of phospholipids, and combining them with hydrophilic polymers and targeting components, the challenge of therapeutic nucleic acids crossing the blood-brain barrier in central nervous system diseases has been overcome, achieving efficient and stable targeted delivery and pharmacokinetic properties.
Patent Information
- Application Number
- CN202580029722.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-25
- Filing Date
- 2025-04-22
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies struggle to effectively package and target the delivery of therapeutic nucleic acids, particularly in central nervous system diseases where the challenge of crossing the blood-brain barrier remains largely unresolved. Furthermore, there are pharmacokinetic issues and potential problems related to toxicity, immunogenicity, and off-target effects.
Lipid nanoparticles (LNDPs) comprising an outer lipid membrane and a core of phospholipids are employed, wherein the outer lipid membrane is conjugated with hydrophilic polymers such as PEG molecules and combined with targeting components such as peptides or antibodies to specifically bind to transferrin receptors (TfR) to improve targeting and stability.
It enhances the targeted delivery efficiency and stability of therapeutic nucleic acids, improves the ability to penetrate the blood-brain barrier, reduces toxicity and immune response, and achieves acceptable pharmacokinetic characteristics, making it suitable for the treatment of central nervous system diseases.
Smart Images

Figure CN123124965A_ABST
Abstract
Description
Reference to sequence list
[0001] This application includes a sequence list that has been electronically submitted in ST.26 XML format, the entire contents of which are incorporated herein by reference. The ST.26 XML sequence list was created on April 4, 2025, named 30664_WO.xml, and has a size of 10 kilobytes. Technical Field
[0002] This disclosure relates generally to the medical field. More specifically, this disclosure relates to compositions comprising lipid nanoparticles (LNDPs) for targeted delivery of nucleic acids, methods of manufacturing LNDPs, and methods of using LNDPs for targeted delivery of nucleic acids after administration to a patient. The LNDPs of this disclosure are helpful in treating diseases, including, in some embodiments, central nervous system (CNS) diseases. Background Technology
[0003] Nucleic acids represent a promising field as therapeutic agents. However, the main challenge in realizing this therapeutic potential remains packaging and delivery technologies that provide stability and protection for therapeutic nucleic acids while enabling targeted transport or delivery to the desired region / therapeutic target after administration to the patient. For central nervous system (CNS) diseases, therapeutic nucleic acids face the additional challenge of crossing the blood-brain barrier (BBB) into the CNS after administration to the patient.
[0004] Proposals for packaging and targeted delivery of therapeutic nucleic acids include linking the nucleic acid to a portion that specifically binds to a therapeutic target, such as an antibody, antibody fragment, or peptide. For example, it has been proposed to conjugate a therapeutic nucleic acid with a peptide (e.g., an RGD peptide or a TAT peptide) or an antibody or fragment thereof (e.g., an antibody-oligonucleotide conjugate (AOC)) to achieve targeted delivery, wherein the peptide or antibody binds to a therapeutic target (such as a cell surface receptor). For CNS diseases, one such target of interest is the transferrin receptor (TfR); it has been proposed to conjugate a therapeutic nucleic acid with an antibody or fragment thereof that specifically binds to the TfR to achieve targeted delivery. (See, for example, McQuiad et al. (2021) PLoS ONE 16:e0252341; and International Patent Application Publications Nos. WO2020 / 144233 and WO 2022 / 026555). While such options may be selectively provided for targeted delivery, they do not address the packaging and protection of the therapeutic nucleic acid.
[0005] Other proposals for packaging and targeted delivery of therapeutic nucleic acids include nanoparticles, such as exosomes, liposomes, and lipid nanoparticles. While these methods can facilitate the delivery of therapeutic nucleic acid agents across cell membranes, they may lack cell specificity and may induce toxicity associated with widespread exposure to therapeutic agents. Furthermore, to date, these technologies still face significant challenges related to the manufacture, encapsulation, and protection and stability of therapeutic nucleic acids, as well as pharmacokinetic issues after administration.
[0006] Therefore, there remains a need to enhance the packaging and targeted delivery of therapeutic nucleic acids to overcome one or more of the challenges mentioned above. Such enhancements must enable the delivery of therapeutic nucleic acids to selective targets with increased efficiency and stability after administration. It is also expected that such enhancements should not be more invasive than the therapeutic molecule and should not be accompanied by unacceptable immunogenicity, toxicity, or off-target issues, exhibiting acceptable pharmacokinetic properties. Such enhancements should also allow for improved manufacturing and should not interfere with the properties of the therapeutic nucleic acid required for the therapeutic indication. Furthermore, for CNS diseases, such enhancements must improve targeting to the BBB and, in some cases, achieve peripheral-systemic delivery of the therapeutic agent to overcome the need for direct invasive delivery of the therapeutic agent into the CNS.
[0007] This disclosure provides lipid nanoparticles (LNDPs) for packaging therapeutic nucleic acids and enhancing their targeted delivery. Embodiments of the LNDPs disclosed herein can also be used to treat CNS diseases and target BBB targets to enhance the delivery of therapeutic nucleic acids into the CNS. Summary of the Invention
[0008] Embodiments of this disclosure include an LNDP comprising an outer lipid membrane composed of phospholipids; and a core located within the outer lipid membrane, wherein a plurality of phospholipids of the outer lipid membrane are conjugated to a hydrophilic polymer (such as polyethylene glycol (PEG) molecules), and wherein the plurality of phospholipids of the outer lipid membrane conjugated to the hydrophilic polymer contain targeting portions conjugated to the hydrophilic polymer.
[0009] According to some embodiments of this disclosure, LNDP is selected from the group consisting of: encapsulated nanocomposites (eNCP), lipid nanoparticles (LNP), liposomes, nanocapsules (NC), nanocrystals (NCR), polymeric lipid nanoparticles (PLNP), nanoemulsions (NE), and protein lipid carriers (PLV).
[0010] In certain implementations, the core is either oily or liquid. In some implementations, the core is solid.
[0011] The LNDP embodiments disclosed herein also include an internal lipid membrane comprising phospholipids, wherein the internal lipid membrane is inside the external lipid membrane.
[0012] Additionally, embodiments of the LNDP disclosed herein include a targeting portion, which is one of a peptide, antibody, Fab, scFv, VHH, or organic compound. In some specific embodiments, the targeting portion specifically binds to TfR. In even further embodiments where the targeting portion specifically binds to TfR, it has an affinity of 0.1 nanomolar (nM) to 500 nM. In some further embodiments, the targeting portion specifically binds to a peripheral cell target. In one specific embodiment, the peripheral cells may be T lymphocytes.
[0013] According to some embodiments of the LNDP disclosed herein, the hydrophilic polymer has a molecular weight of 1 kilodaltons (kDa) to 10 kDa. In some embodiments, the hydrophilic polymer has a molecular weight of 1 kDa to 5 kDa. In some embodiments, the hydrophilic polymer has a molecular weight of 1 kDa to 3 kDa. In some embodiments, the hydrophilic polymer has a molecular weight of approximately 2.5 kDa. According to some embodiments, the hydrophilic polymer is conjugated to multiple phospholipids of the external lipid membrane via maleimide (i.e., via a maleimide reaction). According to embodiments, the hydrophilic polymer is one of a polyethylene glycol (PEG) molecule, a zwitterionic polymer, or OEGMA. According to a more specific embodiment, the hydrophilic polymer is a PEG molecule.
[0014] According to some embodiments of the LNDP disclosed herein, the targeting portion is conjugated to multiple hydrophilic polymers via maleimide. According to a specific embodiment, the hydrophilic polymer is a PEG molecule.
[0015] According to some embodiments of the LNDP disclosed herein, approximately 1% to approximately 5% (i.e., approximately 1% to 5% molar percentage) of the total molar particulate composition is a plurality of phospholipids of an outer lipid membrane to which a hydrophilic polymer is conjugated. According to some embodiments, approximately 1% to approximately 2.5% of the total molar particulate composition is a plurality of phospholipids of an outer lipid membrane to which a hydrophilic polymer is conjugated. According to a specific embodiment, the hydrophilic polymer is a PEG molecule.
[0016] According to some embodiments, approximately 5% to approximately 20% of the hydrophilic polymer conjugated to the phospholipids of the outer lipid membrane has a targeting portion conjugated to the hydrophilic polymer. According to some embodiments, approximately 10% of the hydrophilic polymer conjugated to the phospholipids of the outer lipid membrane has a targeting portion conjugated to the hydrophilic polymer. According to a specific embodiment, the hydrophilic polymer is a PEG molecule.
[0017] Furthermore, embodiments of this disclosure include pharmaceutical compositions comprising the LNDP of this disclosure.
[0018] Additionally, embodiments of this disclosure include methods for targeted delivery of therapeutic nucleic acids to patients. Such methods include: encapsulating the therapeutic nucleic acid within the core of the LNDP of this disclosure, and administering the LNDP containing the therapeutic nucleic acid to the patient. According to some of these embodiments, the therapeutic nucleic acid comprises one or a combination of mRNA, guide RNA (gRNA), microRNA (miRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), interfering RNA (iRNA), antisense oligonucleotide (ASO), Dicer substrate interfering RNA (DsiRNA), miRNA, short hairpin RNA (shRNA), short interfering RNA (siRNA), short activating RNA (saRNA), suppressor tRNA (sup-tRNA), circular RNA (circRNA), and activating RNA (aRNA). Furthermore, according to some embodiments, the administration steps include any of the following: enteric, parenteral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, intradermal, rectal, intravaginal, intraperitoneal, local, mucosal, nasal, buccal, sublingual, and carotid artery administration. Attached Figure Description
[0019] Figure 1 This is a representative illustration of the LNDP disclosed herein.
[0020] Figure 2 This is an exemplary example of a targeted portion of Fab directly conjugated to a PEG molecule, which is conjugated to the phospholipids of the outer lipid membrane, and here is shown to have a maleimide reactive group.
[0021] Figure 3 This is an exemplary example of inserting phospholipids into the outer membrane of phospholipids after the formation of nanoparticles (NPs). The phospholipids have PEG molecules and PEG molecules with a targeting portion attached, the targeting group being conjugated to the PEG molecules.
[0022] Figure 4 The pharmacokinetic evaluation results of the exemplary LNDP of this disclosure in Example 1A are provided.
[0023] Figure 5 Results of exemplary LNDP targeted delivery to the non-central nervous system provided in Example 1A of this disclosure are presented.
[0024] Figure 6 The present disclosure provides results demonstrating exemplary LNDP targeted delivery to the BBB in Example 1 and demonstrates exemplary therapeutic nucleic acid activity.
[0025] Figure 7The pharmacokinetic evaluation results of the exemplary LNDP of this disclosure are provided in Example 2.
[0026] Figure 8 The present disclosure provides an assessment of the cellular level distribution of exemplary LNDP in the brain, based on Example 2.
[0027] Figure 9 Results of exemplary LNDP targeted delivery to the brain in Example 3 of this disclosure are provided.
[0028] Figure 10 It is a graph that demonstrates how encapsulating siRNA in LDNP modified with an anti-CD7 fab fragment enhances siRNA delivery in primary human T cells. Detailed Implementation
[0029] As used herein, lipid nanoparticles (LNDPs) refer to nanoparticle (NP) compositions having an encapsulating core and an outer (i.e., surface) phospholipid membrane. The LNDPs of this disclosure are capable of completely or partially encapsulating (i.e., packaging) nucleic acids within the core. In some embodiments, the LNDPs of this disclosure may comprise a phospholipid bilayer (such as liposomes) or a monolayer phospholipid membrane (such as lipid nanoparticles (LNPs)). Additionally, the LNDPs of this disclosure may comprise a solid core (such as LNPs), a liquid core (such as nanoemulsions (NEs)), or an oily core (such as nanocapsules (NCs)) or combinations thereof. Examples of NPs comprising the LNDPs of this disclosure include LNPs, NEs, NCs, liposomes, lipids, lipid complexes, protein lipid carriers (PLVs), polymers, dendritic polymers, encapsulated nanocomposites (eNCPs), and nanocrystals (NCRs).
[0030] The LNDP of this disclosure includes a hydrophilic polymer, such as a PEG molecule, linked or conjugated to a plurality of phospholipids constituting the outer (i.e., surface) membrane. As used herein, a hydrophilic polymer is an oxygen-containing hydrophilic polymer that has an affinity for water (e.g., the ability to interact with water), including PEG molecules, zwitterionic polymers, and OEGMA. The hydrophilic polymer linked to the phospholipids of this disclosure may independently have linear, branched, and aromatic properties, and have a molecular weight of about 1 kDa to 10 kDa. According to some specific embodiments, the molecular weight of the PEG molecule linked to the respective phospholipid of this disclosure may be about 1 kDa to 4.5 kDa. According to embodiments, the plurality of phospholipids comprising the hydrophilic polymer linked thereto may account for about 1% to about 5% of the total molar percentage of the phospholipids of the outer lipid membrane. In some specific embodiments, the total molar percentage of the phospholipids comprising the hydrophilic polymer linked thereto is about 1.5%. In even more specific embodiments, the hydrophilic polymer is a PEG molecule.
[0031] The LNDP disclosed herein also includes a targeting portion linked or conjugated to a plurality of hydrophilic polymers (e.g., PEG molecules) linked to phospholipids constituting the outer (i.e., surface) membrane. According to embodiments of the LNDP of this disclosure, the targeting portion is linked or conjugated to approximately 10% to approximately 20% of the phospholipid-linked PEG molecules. According to even more specific embodiments, the targeting portion is linked or conjugated to approximately 10% of the phospholipid-linked PEG molecules.
[0032] As used herein, a targeting moiety refers to a chemical portion (e.g., an antibody or fragment thereof (such as scFV, VHH, or Fab), peptide, receptor, etc.) that selectively binds to a therapeutic target (such as a cell surface receptor). The targeting moiety facilitates the delivery of LNDPs to specific cells through this selective binding to the therapeutic target (such as a cell surface receptor), thereby aiding in the internalization of the packaged therapeutic nucleic acid into the cell. According to some implementations that can be used to help treat CNS diseases, the targeting moiety is specific to BBB targets.
[0033] According to some embodiments, LNDPs, as described herein, can be used to deliver nucleic acids to immune cells. In one specific embodiment, the immune cells are T lymphocytes (or “T cells”). In this embodiment, the delivered nucleic acid may encode one or more proteins to be expressed by the T cells, and / or may be used to edit the genetic material of the T cells, causing the T cells to express one or more proteins. In one embodiment, the nucleic acid delivered by the LNDP is used to encode a chimeric antigen receptor (CAR), thereby making the T cell a CAR-T cell. The LNDP can deliver nucleic acid cargo ex vivo or in vivo. Targeting portions provided on or conjugated to the outer surface of the LNDP for this application can target molecules expressed on the surface of T cells, such as CD5, CD7, or CD8, etc. (See Billingsley et al., “In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism.” Small 2024, 20, 2304378).
[0034] As used interchangeably with the terms “specific to,” “specifically bind,” or “specifically target” in this document, the term refers to the ability of a targeting moiety to bind and / or associate with a specific target molecule (such as a protein or receptor) above background or non-target levels. In some embodiments, “specific to” can be demonstrated by a measurement of the affinity (Kd) of the target relative to a non-target.
[0035] As used interchangeably herein, the terms “conjugated” or “linked” refer to the association, attachment, linkage, or other engagement of a first molecule or compound (e.g., NP) with a second molecule or compound (e.g., a hydrophilic polymer, such as a PEG molecule (or, for example, a PEG molecule having a target portion thereto)). Conjugation of a PEG molecule (or a PEG molecule having a target portion thereto) can be achieved through directional conjugation (e.g., with a reactive group, such as a thiol-based reactive group, such as maleimide, see [link]). Figure 2 (Examples) or via PEG molecules already conjugated thereto (or PEG molecules with a target portion attached thereto, see Example). Figure 3 (Example) Phospholipids are inserted into the phospholipid outer membrane after NP formation. It should be understood that a combination of phospholipids with PEG molecules inserted after NP formation and directional conjugation to the target portion can be used.
[0036] As used herein, a "connector" refers to an atom, group of atoms, molecule, or compound, such as an amino acid or a group of amino acids, containing at least one bond that attaches or links a molecule or compound (e.g., NP) to or to another molecule or compound (e.g., a PEG molecule or a PEG molecule having a target moiety thereto). A connector may be "unstable" or "cleavable," meaning that the connector can be cleaved (e.g., by acidic pH or an enzyme). Alternatively, a connector may be "stable" or "non-cleavable," meaning that the connector cannot be cleaved under physiological conditions. According to this disclosure, connectors may also include hydrolyzable and / or enzymatically degradable connectors. Connectors may also attach a variety of therapeutic compositions to the multispecific binding molecules of this disclosure. Additionally, examples of connectors include thiol-based reactive groups (e.g., maleimide, mercapto, haloacetyl, thiosulfonate, disulfide), amine-based groups (e.g., N-hydroxysuccinimide ester, imine ester, etc.), aldehyde-based reactive groups (e.g., acylhydrazides and alkoxyamines), and carbohydrate-based groups (e.g., natural Fc polysaccharides, engineered polysaccharides, etc.).
[0037] As used herein, therapeutic nucleic acids refer to nucleic acid molecules intended for the treatment of diseases. Examples of therapeutic nucleic acids include edited nucleic acids, including, for example, DNA, mRNA, guide RNA (gRNA), microRNA (miRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). Additionally, therapeutic nucleic acids as referred to herein include interfering RNA (iRNA), antisense oligonucleotides (ASO), Dicer substrate interfering RNA (DsiRNA), miRNA, short hairpin RNA (shRNA), short interfering RNA (siRNA), short activating RNA (saRNA), suppressor tRNA (sup-tRNA), circular RNA (circRNA), and small interfering RNA (siRNA). Furthermore, the therapeutic nucleic acids disclosed herein may include activating RNA (aRNA). As used herein, therapeutic nucleic acids can be single-stranded or double-stranded nucleic acids having therapeutic applications (i.e., applications for the diagnosis and / or treatment of diseases, symptoms, or conditions). The therapeutic nucleic acids disclosed herein may contain one or more modified nucleotide residues or bonds.
[0038] As used herein, “nucleic acid” refers to a polymer of nucleotides. While it can contain any type of nucleotide unit, the term is generally applicable to polymers of nucleotides in DNA, cDNA, and / or RNA. Polynucleotides are used to refer to single-stranded (ss) nucleic acids, double-stranded (ds) nucleic acids, and DNA, cDNA, and / or RNA made from nucleotides or nucleoside analogs that can be identified by their sequences, which are typically presented in a 5' to 3' orientation (as coding strands), where 5' and 3' indicate the bond formed between the 5' hydroxyl group of one nucleotide and the 3' hydroxyl group of the next nucleotide. For a coding strand presented in a 5'–3' orientation, its complementary sequence (or non-coding strand) is the strand that hybridizes to that sequence according to Watson-Crick base pairing. Thus, as used herein, the complementary sequence of a nucleic acid (such as a polynucleotide) is the same as the “reverse complementary sequence,” and describes the nucleic acid in its native form that will pair with the bases of the nucleic acid under discussion.
[0039] The therapeutic nucleic acids disclosed herein can be presented within a vector. As used herein, "vector" means a nucleic acid molecule capable of transporting another nucleic acid sequence (or multiple nucleic acid sequences) linked thereto into a host cell or genome. One type of vector is a "plasmid," which refers to a circular DNA loop, typically double-stranded (ds), in which an additional DNA segment can be linked. Another type of vector is a viral vector, in which an additional DNA segment can be linked into a viral genome. Some vectors are capable of autonomous replication in the host cells to which they are introduced (e.g., bacterial vectors with a bacterial origin of replication). Furthermore, some vectors are capable of directing the expression of a gene operatively linked thereto (e.g., a gene encoding a foreign peptide or protein of interest) when combined with appropriate control sequences, such as promoter and operator sequences and a replication initiation site. Such vectors are often referred to as "expression vectors" and may also include a multiple cloning site for inserting a gene encoding a protein of interest. Alternatively, a gene encoding a peptide or protein of interest can be introduced via site-directed mutagenesis techniques such as Kunkel mutagenesis. See, for example, Handa et al., Rapid and Reliable Site-Directed Mutagenesis Using Kunkel's Approach, Methods in Molecular Biology, Vol. 182: In Vitro: Mutagenesis Protocols, 2nd ed.
[0040] According to some implementation schemes, the vector may include a “viral vector,” as used herein, which refers to a vector derived from a naturally occurring or modified virus, particularly a recombinant AAV (“rAAV”) vector or a baculovirus vector (e.g., the Autographa californica nucleopolyhedrome (AcNPV) vector). “Recombinant adeno-associated virus,” “recombinant AAV,” and “rAAV” are synthetic polynucleotide vectors containing one or more heterologous sequences (i.e., non-AAV-derived nucleic acid sequences) flanked by at least one AAV ITR sequence. Such rAAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been infected (or expresses a suitable helper virus) expressing the AAV rep and cap gene products (i.e., the AAV Rep and Cap proteins).
[0041] As used herein, “engineering” of a nucleic acid sequence refers to a nucleotide sequence with alterations obtained through genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning; transfection, transformation and other gene transfer techniques; homologous recombination; site-directed mutagenesis; and gene fusion. For example, “engineering” can refer to alterations made relative to a given wild-type nucleotide or amino acid sequence, such as the addition, deletion, and / or substitution of nucleic acid residues or amino acid residues.
[0042] As used herein, in the context of two nucleotide sequences or two amino acid sequences, "sequence identity" means the same residues in two sequences when compared within a specified comparison window to obtain the maximum correspondence.
[0043] As may be used interchangeably herein, the terms “patient,” “subject,” and “individual” refer to a person. In some embodiments, a patient is further characterized as having a CNS disease, condition, or illness (e.g., a CNS neurodegenerative disease). In some embodiments, a patient may be further characterized as being at risk of developing a CNS disease, condition, or illness.
[0044] As used herein, “treatment” means the act of providing care to an individual in need, such as by administering a therapeutic agent to an individual with the aim of improving the individual’s health and / or well-being regarding an existing disease, condition, or illness, or preventing or reducing the likelihood of the disease, condition, or illness occurring. Treatment may also involve reducing the frequency or severity of at least one sign, symptom, or contributing factor to a disease, condition, or illness experienced by the individual.
[0045] As used herein, “administration” means the delivery of a substance (e.g., lipid nanoparticles or pharmaceutical compositions thereof provided herein) to an individual in a pharmacologically useful manner (e.g., for the treatment of an individual’s disease, symptom, or condition). Administration can be performed via any route, including enterally (e.g., orally), parenterally, intravenously, intramuscularly, intra-arterially, intramedullaryly, intrathecally, subcutaneously, intravenously, transdermally, intradermally, rectally, intravaginally, intraperitoneally, topically (e.g., by powder, ointment, cream, and / or drops), mucous membranes, nose, buccally, sublingually; by endotracheal instillation, bronchial instillation, and / or inhalation; and / or as an oral spray, nasal spray, and / or aerosol. Specifically considered routes include IV injection (e.g., systemic intravenous injection), IC (e.g., intravascular carotid artery injection), SC injection, ICV injection, ICM injection, IPM injection, IT injection, or combinations thereof.
[0046] As used herein, "effective amount" means the amount, concentration, or dose of a therapeutic agent or pharmaceutical composition thereof that, when administered to an individual in need in a single or multiple doses, provides the desired effect (i.e., produces a clinically measurable difference in the individual's condition). An effective amount can be readily determined by those skilled in the art using known techniques and by observing results obtained in similar circumstances. In determining the effective amount for an individual, many factors are considered, including but not limited to: the species of the mammal; its size, age, diet, and general health; the specific disease, symptom, or condition involved; the extent or severity of the disease, symptom, or condition; the individual's response; the therapeutic agent administered; the mode of administration; the bioavailability characteristics of the administered formulation; the chosen dosing regimen; the use of concomitant medications; and other relevant factors.
[0047] As used herein, "pharmaceutical composition" means a composition or therapeutic agent mixed with at least one pharmaceutically acceptable chemical component, such as, but not limited to, a carrier, stabilizer, diluent, dispersant, suspending agent, thickener, excipient, etc.
[0048] As used herein, when referring to materials such as carriers or diluents, “pharmaceutically acceptable” means that it does not eliminate the biological activity or properties of the therapeutic agent and is relatively non-toxic (i.e., the material can be administered to an individual without causing undesirable biological effects or interacting in a harmful manner with any component of the composition containing it).
[0049] As used herein, “pharmaceuticalally acceptable carrier” means a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating material, which participates in the delivery or transport of a therapeutic agent within or to an individual so that the therapeutic agent can perform its intended function. Other ingredients that may be included in the pharmaceutical compositions used in the practice of this invention are known in the art and described, for example, in Remington's Pharmaceutical Sciences, 21st edition, University of the Sciences in Philadelphia, PA (2006).
[0050] According to some embodiments of this disclosure, the LNDP disclosed herein can also be used to treat CNS diseases by targeting BBB targets to enhance the delivery of therapeutic nucleic acids to the CNS. As used herein, “CNS disease, condition, or symptom” or “CNS disease” means a disease, condition, or symptom affecting the brain (e.g., the frontal, occipital, parietal, and / or temporal lobes, including regions such as, for example, the amygdala, basal ganglia, Broca's area, cerebellum, corpus callosum, hypothalamus, medulla oblongata, and thalamus), brainstem, glial cells (e.g., astrocytes, ependymal cells, microglia, and oligodendrocytes), neurons, and / or spinal cord. Examples of CNS diseases, conditions, or symptom include, but are not limited to, attention deficit hyperactivity disorder (ADHD), autism, Alzheimer's disease (AD), cancer, epilepsy, frontotemporal dementia (FTD), Huntington's disease (HD), infection / inflammation, migraine, multiple sclerosis (MS), Parkinson's disease (PD), seizures, and stroke. In some cases, the use of LNDP to treat CNS diseases may include administration to an individual's CNS via direct (i.e., central) injection, which may be an ICV injection, ICM injection, IPM injection, IT injection, or a combination thereof. In other cases, administration may be via peripheral injection, including IV and SC.
[0051] As mentioned in this article, BBB targets are membrane receptors located on the apical side of the endothelial BBB, and include, but are not limited to, TfR, low-density lipoprotein receptor-associated protein 1 (LRP1), LRP2 or macroprotein / GP330, LRP3, LRP5, LRP6, LRP8, insulin-like growth factor receptor 1 (IGF1R), CD98 heavy chain (SLC3A2), small subunit 1 of large amino acid transporter 1 (LAT-1), insulin receptor, low-density lipoprotein (LDL) receptor, CDC50A, etc. As used in this article, TfR includes two isotypes, TfR1 and TfR2. This article is of particular interest to TfR1, whose exemplary nucleotide sequences can be found in NCBI reference sequences NM_003234.4 (human), NM_011638.4 (mouse), NM_001257303.1 (non-human primates), XM_003310190.3 (non-human primates), and NM_022712.1 (rat). Similarly, exemplary amino acid sequences of the TfR1 monomer can be found in NCBI reference sequences NP_003225.2 (human; SEQ ID NO:1), NP_035768.1 (mouse), NP_001244232.1 (non-human primates), XP_003310238.1 (non-human primates), and NP_073203.1 (rat). However, those skilled in the art will understand that other examples of TfR1 sequences can be readily obtained using publicly available databases such as, for example, GenBank and UniProt.
[0052] Furthermore, unless the context explicitly requires the existence of one and only one element, referring to an element with the indefinite article "a" or "a kind" does not preclude the possibility of the existence of more than one element. Therefore, the indefinite article "a" or "a kind" usually means "at least one".
[0053] As used interchangeably herein, “about” and / or “approximately” means within a statistically significant range of one or more values, such as, for example, specified concentration, length, molecular weight, pH, sequence similarity, time range, temperature, volume, etc. Such values or ranges can be on the order of typically within 20%, more typically within 10%, and even more typically within 5% of a given value or range. The permissible variations covered by “about” and / or “approximately” will depend on the specific system studied and will be readily understood by those skilled in the art. Components targeting LNDP
[0054] Lipid nanoparticles for delivering nucleic acid cargo have been known for over a decade and are composed of several different classes of lipid molecules that impart their properties to the nanoparticles. The classes of lipid molecules that can be used to prepare LNDP-targeting molecules as described in this disclosure include, but are not limited to, the following. Ionizable lipids
[0055] Ionizable lipids typically have a pKa value that makes them neutral at physiological pH levels (such as in the bloodstream or after LNDPs cross the cell membrane), but positively charged as pH decreases (such as when associated with endosomes) to facilitate the escape of nucleic acid cargo from endosomes. Typically, the pKa of such lipids is between 6 and 7. The ionizable lipids that may be included in LNDPs as described herein include, but are not limited to, 9Z,12Z-octadecadienoic acid, 3-[4,4-bis(octoxy)-1-oxobutoxy]-2-[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]propyl ester (LP-01); 4-(dimethylamino)butyric acid, (6Z,9Z,28Z,31Z)-heptadec-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate (D-Lin-MC3-DMA or MC3); and 9-heptadecyl 8-((2-hydroxyethyl)[6-oxo-6-(undecoxy)hexyl]amino)octanoate (SM-102), etc. Ionizable lipids typically constitute 35% to 60% (molar ratio) of LNDPs. Structural lipids
[0056] Structural lipids help maintain the structure and rigidity of LNDPs. Typically, structural lipids are cholesterol or cholesterol analogs. Structural lipids usually constitute 0% to 60% (molar ratio) of LNDPs. Phospholipids ("helper" lipids)
[0057] Phospholipids provide a degree of flowability to LNDPs while maintaining particle integrity. Phospholipids that can be used in LNDPs as described herein include, but are not limited to, distearylphosphatidylcholine (DSPC) and 1,2-distearyl-sn-glycerol-3-phosphoethanolamine-poly(ethylene glycol) (DSPE). Phospholipids typically constitute 0% to 30% (molar ratio) of the LNDP. Polymer-conjugated lipids
[0058] Polymer-conjugated lipids (including hydrophilic polymers in embodiments) can be used to modulate particle size and charge. Several polymers have been described herein. In one embodiment, the polymer is a polyethylene glycol (PEG) polymer with a molecular weight of about 1 kilodaltons to 10 kilodaltons. In some embodiments, the lipid component of the polymer-conjugated lipid is a phospholipid. In such embodiments, the phospholipid of the polymer-conjugated lipid may be the same as the phospholipids referred to above as "auxiliary lipids". In other embodiments, the phospholipid of the polymer-conjugated lipid may be different from the phospholipids referred to above as "auxiliary lipids". In other embodiments, the lipid component of the polymer-conjugated lipid is not a phospholipid. In specific implementations, the polymer-conjugated lipid can be 1,2-distearate-sn-glycerol-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG); 1,2-dimyristoyl-sn-glycerol-3-methoxypolyethylene glycol (DMG-PEG); or 2-[(polyethylene glycol)-2000]-N,N-(di)tetradecylacetamide (ALC-0159), etc. The polymer-conjugated lipid typically accounts for 1% to 5% (molar ratio) of LNDP. Targeted lipids
[0059] As described herein, targeted lipids are lipids conjugated to a targeting moiety, such as an antibody or a portion thereof, a peptide, a sugar, etc. In one specific embodiment, the targeted lipid also includes a polymer. LNDPs can be generated from a precursor (such as a maleimide moiety), and the targeting moiety is added after purification of the LNDPs. Specific targeted lipids are described herein. Targeted lipids are typically present in an amount of 5% to 20% relative to the polymer-conjugated lipids, or 0.05% to 1% (molar ratio) of the total LNDPs.
[0060] Exemplary LNDP compositions are provided in Table 1.
[0061] Example Example 1A Exemplary lipid nanoparticles
[0062] The exemplary LNDP of this disclosure comprises an outer lipid membrane composed of phospholipids, wherein a plurality of phospholipids are conjugated to PEG molecules. Exemplary embodiments of the LNDP core composition include ionizable lipids (e.g., 45 mol% of 9Z,12Z-octadecadienoic acid, 3-[4,4-bis(octyloxy)-1-oxobutoxy]-2-[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]propyl ester (LP-01), cholesterol present in 43.5 mol% and distearate phosphatidylcholine (DSPC) present in 9 mol%).
[0063] According to a specific exemplary embodiment, the lipids of the outer lipid membrane are independently conjugated with PEG, such as 1,2-distearate-sn-glycerol-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG; PEG length: 500 Da to 4000 Da) or 1,2-dimyristoyl-sn-glycerol-3-methoxypolyethylene glycol (DMG-PEG; PEG length 500 Da to 3400 Da), and these PEG-lipids may be present in this embodiment at a concentration of about 2.25 mol% of the particle. According to a specific exemplary embodiment, about 2 mol% of the PEG-lipids of the outer lipid membrane are independently DMG-PEG (PEG MW about 2 kDa), and about 0.25 mol% of the phospholipids of the outer lipid membrane are independently DSPE, and conjugated with about 2 kDa of PEG to produce DSPE-PEG. DSPE-PEG is further conjugated with a ligand, such as Fab targeting the transferrin receptor. According to an exemplary embodiment, Fab contains an engineered cysteine residue at residue 124 in the heavy chain constant region. An exemplary Fab contains the following amino acid sequence:
[0064] Heavy chain:
[0065] QSLEESGGDLVKPEGSLTLTCTASGFSFSGSYWICWVRQAPGKGLEWIGCIYSTSGGRTYYASWVKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGDDSISDAYFDLWGPGTL VTVSSASTKGPCVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH (SEQ ID NO: 1);
[0066] Light chain:
[0067] ALDMTQTASPVSAAVGGTVTINCQSSQSVYNNNRLAWYQQKPGQPPKLLIYDASTLASGVPSRFKGSGSGTQFTLTISGVQSDDSATYYCQGTYFSSGWSWAFGGGTEVVV KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 2).
[0068] Additionally, according to an exemplary embodiment, the LNDP kernel composition comprises a hydrophobic core and contains a nucleic acid (e.g., a therapeutic nucleic acid). A further exemplary embodiment includes an oily kernel. An exemplary embodiment includes siRNA nucleic acid. Another exemplary embodiment includes mRNA encapsulated therein. Encapsulation of therapeutic nucleic acids
[0069] The encapsulation of nucleic acids according to this disclosure can be accomplished substantially as described below. In short, for example, mRNA encoding the Cre protein is encapsulated in an exemplary LNDP of this disclosure as follows:
[0070] a. The lipids were combined in 200% standard alcohol ethanol in the following specific ratios: 2.25 mol% DSPE-PEG (2kDa), 0.25 mol% DSPE-PEG-maleimide (2kDa), 45 mol% LP-01 (9Z,12Z-octadecadienoic acid, 3-[4,4-bis(octyloxy)-1-oxobutoxy]-2-[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]propyl ester), 43.5 mol% cholesterol and 9 mol% DSPC (distearylphosphatidylcholine).
[0071] b. If the lipids are not completely dissolved, repeat the process.
[0072] c. Prepare an RNA solution in water and mix it with sodium citrate buffer.
[0073] d. Use microfluidic channels to mix the aqueous and lipid solutions. The following exemplary parameters can be used: a flow-to-volume ratio of 3:1 (RNA:lipid), and a total flow rate of 12 mL / min.
[0074] e. Perform buffer exchange by preparing a PD-10 column to exchange ethanol and citrate buffer for 0.1M PBS. Targeted conjugation with lipid nanoparticles
[0075] The exemplary LNDP of this disclosure may have a targeting moiety conjugated substantially as described herein. Redox thiol-functionalized Fab is provided to the LNDP at a 4:1 molar ratio (maleimide-PEG-DSPE:fab fragment) for 4 hours. An isotype lipid nanoparticle control can be prepared in the same manner, but using the same fab or a non-targeted analogue with another structure. A naked lipid nanoparticle control can also be prepared in the same manner, but the functionalized lipid-PEG molecule is replaced with a non-functionalized lipid-PEG molecule (e.g., without reactive groups that associate with PEG molecules or other hydrophilic polymers). Pharmacokinetic (Pk) assessment
[0076] The pharmacokinetics of the exemplary LNDP of this disclosure can be evaluated as follows. Briefly, 8-week-old female C57BL / 6 mice were administered 1 mg / kg of the following: (i) the LNDP of this disclosure, which contains a transferrin receptor targeting moiety and is encapsulated with Cy3-labeled siRNA, or (ii) PBS, or (iii) control isotype lipid nanoparticles, or (iv) naked lipid nanoparticles. The levels of the corresponding molecules were determined by fluorescence imaging of bulk tissue and flow cytometry of homogenized tissue at 4 and 18 hours, respectively. Following procedures substantially as described herein, approximately 65% to 95% of endothelial cells were positive for the fluorescent Cy3-labeled siRNA, reaching peak positivity, approximately 4 to 48 hours later. Clearance from circulation was demonstrated by 48 hours. Results are provided in Figure 4 The study also showed that PK was enhanced compared to both naked lipid nanoparticle control and homologous lipid nanoparticle control. Targeted delivery - peripheral
[0077] The exemplary targeting effect of the LNDP of this disclosure on non-CNS organs can be demonstrated by the following methods. Briefly, in two separate studies, 8-week-old female C57BL / 6 mice were administered via IV at 2 mg / kg of the following: (I) the LNDP of this disclosure, comprising a transferrin receptor targeting moiety and encapsulated with Alexafluor647-labeled siRNA, or (ii) PBS, or (iii) control isotype lipid nanoparticles, or (iv) naked lipid nanoparticles. Mice were sacrificed four hours after administration, and the levels of the corresponding molecules in brain, heart, spleen, lung, kidney, stomach, and liver tissues were determined. Results are provided in Figure 5Furthermore, it was demonstrated that the exemplary LNDP of this disclosure exhibits enhanced targeting compared to homologous lipid nanoparticle controls and naked lipid nanoparticle controls. Targeted delivery - blood-brain barrier
[0078] The exemplary LNDP of this disclosure can be demonstrated for its targeting of the blood-brain barrier and therapeutic nucleic acid activity by means of the following methods. Briefly, in two separate studies, 8-week-old female C57BL / 6 mice were administered via IV at 2 mg / kg of the following: (i) the LNDP of this disclosure, which contains a transferrin receptor targeting moiety and is encapsulated with Cy3-siRNA or Cre mRNA; (ii) PBS; (III) control isotype lipid nanoparticles; or (IV) naked lipid nanoparticles. Mice were sacrificed four hours after administration, and the levels of the corresponding molecules in the brain and Cre3 mRNA activity were determined. Results are provided in Figure 6 Furthermore, it was demonstrated that, compared with isotype lipid nanoparticle controls and naked lipid nanoparticle controls, the exemplary LNDP of this disclosure has enhanced targeting and therapeutic nucleic acid activity. Example 1B Targeted delivery - enhanced in vitro activity
[0079] The targeted enrichment of therapeutic nucleic acid activity achieved by the exemplary LNDP of this disclosure can be demonstrated in the following manner, and this can be accomplished substantially in the manner described in the method provided in Example 1A. In short, N2A and BV2 cells are loaded at 5 × 10⁻⁶ cells / day. 3 Cells were cultured per well and treated with siRNA at doses ranging from 0 nM to 100 nM and incubated for 24 hours. The siRNA was formulated as (i) the LNDP of this disclosure containing the transferrin receptor targeting moiety, or (ii) naked lipid nanoparticles, or (III) control isotype lipid nanoparticles, or (IV) PBS. HPRT expression was measured by Taqman qPCR and normalized to actin-b expression. Results normalized to the PBS-treated groups are presented in Table 2, and the results indicate that the exemplary LNDP of this disclosure has enhanced targeting and therapeutic nucleic acid activity compared to the isotype lipid nanoparticle control and the naked lipid nanoparticle control. LNDP with TfR-binding fab showed enriched delivery to BV2 cells (a mouse microglia cell line) and N2A cells (a mouse neuroblastoma cell line) when delivering HPRT siRNA, compared to unmodified LNDP and LNDP modified with isotype control fab.
[0080] Example 1C Brain enrichment in vivo
[0081] LNDP with TfR-binding fab resulted in enriched delivery to the brain compared to unmodified LNDP and LNDP modified with isotype control fab when delivering Alexafluor647-tagged HPRT siRNA (encapsulated substantially as described in the method provided in Example 1A). Delivery was quantified by ex vivo in vivo imaging (IVIS) and expressed as total flux (photons / second, p / s). Results are shown in Table 3.
[0082] Example 2 Exemplary lipid nanoparticles
[0083] The exemplary LNDP of this disclosure comprises an outer lipid membrane composed of phospholipids, wherein a plurality of phospholipids are conjugated to PEG molecules. Exemplary embodiments of the LNDP core composition include ionizable lipids (e.g., 50 mol% of 4-(dimethylamino)-butyric acid, (6Z,9Z,28Z,31Z)-heptadec-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate (D-Lin-MC3-DMA), cholesterol present in 37.5 mol% and distearate phosphatidylcholine (DSPC) present in 10 mol%). Another exemplary embodiment of the LNDP core composition includes ionizable lipids (e.g., 45 mol% of 9Z,12Z-octadecadienoic acid, 3-[4,4-bis(octoxy)-1-oxobutoxy]-2-[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]propyl ester (LP-01), cholesterol present in 43.5 mol% and distearate phosphatidylcholine (DSPC) present in 9 mol%).
[0084] According to a particular exemplary embodiment, the lipids at the external lipid membrane independently contain approximately 2 kDa of DMG-PEG, which accounts for approximately 2.5% of the total lipids in the LNP. According to some embodiments, 2.5% to 25% of the total PEG-lipids may be replaced with approximately 2 kDa of DSPE-PEG-glucose.
[0085] Additionally, according to an exemplary embodiment, the LNDP kernel composition comprises a hydrophobic core and contains a nucleic acid (e.g., a therapeutic nucleic acid). A further exemplary embodiment includes an oily kernel. An exemplary embodiment includes siRNA nucleic acid. Another exemplary embodiment includes mRNA encapsulated therein. Encapsulation of therapeutic nucleic acids
[0086] The encapsulation of nucleic acids according to this disclosure can be performed substantially in the manner described in the method provided in Example 1A. Pharmacokinetic (Pk) assessment
[0087] The pharmacokinetics of the exemplary LNDP of this disclosure can be evaluated according to the following procedure. Briefly, 8-week-old male BALB / c mice were fasted for 24 hours and then administered 2 mg / kg of the following substances via tail vein injection: (i) the LNDP of this disclosure, which contains the GLUT1 targeting moiety and is encapsulated with Alexafluor647-labeled siRNA, (ii) PBS, or (iii) naked lipid nanoparticles. Thirty minutes after sample injection, 200 μL of a 20% glucose PBS solution was administered intraperitoneally. The levels of the corresponding molecules were determined by fluorescence imaging of bulk tissues at 4 to 6 hours. Results are provided in Figure 7 Furthermore, it was demonstrated that exemplary LNDPs modified with glucose and carrying siRNA cargo exhibited enhanced brain localization. Therapeutic nucleic acid accumulation at the cellular level
[0088] The cellular distribution of exemplary LNDP in the brain can be assessed as follows. Briefly, 8- to 10-week-old female C57BL / 6J mice were fasted for 24 hours and then administered 2 mg / kg of the following substances via tail vein (IV) or carotid artery (IC) injection: (i) exemplary LNDP carrying Cy3-labeled siRNA or (ii) PBS. Thirty minutes after injection, 200 μL of a 20% glucose PBS solution was administered intraperitoneally. The levels of the corresponding molecules at the brain cellular level were determined by flow cytometry 24 hours post-injection. Results are provided in… Figure 8 Furthermore, it was demonstrated that the glucose-modified exemplary LNDP of the present invention carrying siRNA cargo exhibited the ability to penetrate the BBB. Example 3 Exemplary lipid nanoparticles
[0089] The exemplary LNDP of this disclosure comprises an outer lipid membrane composed of phospholipids, wherein a plurality of phospholipids are conjugated to PEG molecules. Exemplary embodiments of the LNDP core composition include ionizable lipids (e.g., 45 mol% of 9Z,12Z-octadecadienoic acid, 3-[4,4-bis(octyloxy)-1-oxobutoxy]-2-[[[[3-(diethylamino)propoxy]carbonyl]oxy]methyl]propyl ester (LP-01), cholesterol present in 43.5 mol% and distearate phosphatidylcholine (DSPC) present in 9 mol%).
[0090] According to a specific exemplary embodiment, the lipids of the outer lipid membrane are independently polymer-lipid conjugates, such as 1,2-distearate-sn-glycerol-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG; PEG length: 500 Da to 4000 Da) or 1,2-dimyristoyl-sn-glycerol-3-methoxypolyethylene glycol (DMG-PEG; PEG length 500 Da to 3400 Da), and in this embodiment may be present at a concentration of about 2.25 mol% of the particle. According to a specific exemplary embodiment, about 2 mol% of the LNDP of the outer lipid membrane is lipid of the outer lipid membrane and is independently DMG conjugated with about 2 kDa of PEG, and about 0.25 mol% of the LNDP is independently DSPE, which is conjugated with about 2 kDa of PEG to produce DSPE-PEG. DSPE-PEG is further conjugated with a ligand, such as a peptide targeting the human transferrin receptor. According to an exemplary embodiment, the peptide comprises a target binding region containing a sequence of approximately 7 to 20 amino acids and a peptide or PEG (approximately 88 Da to 700 Da) linker connected to the C-terminus of the binding region. The linker region comprises dibenzocyclooctylene (DBCO) or tetrazine. An exemplary peptide comprises the following amino acid sequence:
[0091] T7 peptide: HAIYPRH (SEQ ID NO: 6) (European Journal of Biochemistry, 2001, 268(7), 2004–2012.); and
[0092] Lilly proprietary peptide: amino acid sequence (not shown).
[0093] Additionally, according to an exemplary embodiment, the LNDP kernel composition comprises a hydrophobic core and contains a nucleic acid (e.g., a therapeutic nucleic acid). A further exemplary embodiment includes an oily kernel. An exemplary embodiment includes siRNA nucleic acid. Another exemplary embodiment includes mRNA encapsulated therein. Encapsulation of therapeutic nucleic acids
[0094] The encapsulation of nucleic acids according to this disclosure can be performed substantially in the manner described in the method provided in Example 1A. Targeted conjugation with lipid nanoparticles
[0095] The exemplary LNDP of this disclosure may have a targeting moiety conjugated substantially as described herein. A DBCO-functionalized peptide is provided to the LNDP at a 2:1 molar ratio (azide-PEG-DSPE:peptide) for 40 hours. Targeted delivery - brain
[0096] The brain-targeted delivery of the exemplary LNDP of this disclosure can be evaluated as follows. Briefly, 19-week-old female C57BL / 6NTac-Tfrctm7330.1_B-F11(TFRC*)Tac were administered 2 mg / kg of the following via IV: (i) the LNDP of this disclosure, comprising a transferrin receptor-targeting moiety and encapsulated with Alexafluor647-labeled siRNA, (ii) PBS, (III) naked lipid nanoparticles, or (iv) LNDP containing T7 protein. Mice were sacrificed four hours after administration, and the levels of the corresponding molecules in the brain and Cre3 mRNA activity were determined. Results are provided in Figure 9 The study demonstrated that the exemplary LNDP of this disclosure exhibits enhanced targeting and therapeutic nucleic acid activity compared to homologous lipid nanoparticle controls and naked lipid nanoparticle controls. Four hours later, the levels of the corresponding molecules were determined by fluorescence imaging. Following the procedures described herein, a 6-fold increase in total brain fluorescence signal was observed in the Lilly proprietary peptide-targeted nanoparticles compared to non-targeted nanoparticles. Results are shown in... Figure 9 middle. Example 4 In vitro delivery to T cells
[0097] The targeted delivery of the exemplary LNDP of this disclosure to T cells can be evaluated in the following manner. The CD7 targeting portion (in this case, the fab fragment) can be delivered substantially as described in the method provided in Example 1A. Briefly, cultured primary human T cells are administered any of the following substances in a dose range: (i) the LNDP of this disclosure, which contains the CD7 targeting portion and is encapsulated with HPRT siRNA, (ii) PBS, (iii) naked lipid nanoparticles, or (iv) cholesterol-labeled HPRT siRNA. Cells are incubated for 24 hours after administration, and the level of gene expression silencing is quantified by qPCR, and HPRT mRNA activity is determined. Results are provided in Figure 10 The study demonstrated that, compared with naked lipid nanoparticles and lipid-siRNA controls, the exemplary LNDP of this disclosure has enhanced targeting and successful nucleic acid delivery. sequence list
[0098] SEQ ID NO.1: An exemplary heavy chain Fab targeting TfR, containing amino acid sequences.
[0099] QSLEESGGDLVKPEGSLTLTCTASGFSFSGSYWICWVRQAPGKGLEWIGCIYSTSGGRTYYASWVKGRFTISKTSSTTVTLQMTSLTAADTATYFCARGDDSISDAYFDLWGPGTLVTVSSASTKGPCVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
[0100] SEQ ID NO.2: Amino acid sequence of an exemplary light chain Fab targeting TfR
[0101] ALDMTQTASPVSAAVGGTVTINCQSSQSVYNNNRLAWYQQKPGQPPKLLIYDASTLASGVPSRFKGSGSGTQFTLTISGVQSDDSATYYCQGTYFSSGWSWAFGGGTEVVVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0102] SEQ ID NO.3: Cre mRNA sequence
[0103]
[0104] SEQ ID NO.4: HPRT siRNA sense strand
[0105] UCCUAUGACUGUAGAUUUUAU
[0106] SEQ ID NO.5: HPRT siRNA antisense strand
[0107] AUAAAAUCUACAGUCAUAGGAAU
[0108] SEQ ID NO.6: T7 peptide
[0109] HAIYPRH
[0110] SEQ ID NO.7: Amino acid sequence of an exemplary heavy chain Fab targeting CD7.
[0111] EVQLVESGGGLVKPGGSPRLSCAAYGVTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTIEAVAGHFDYWGQG TLVTVSSASTKGPCVFPLAPSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
[0112] SEQ ID NO.8: Amino acid sequence of an exemplary light chain Fab targeting CD7.
[0113] IQMTQSPSTLSASSVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNNYSPTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Claims
1. A lipid nanoparticle for delivery, the lipid nanoparticle comprising: An external lipid membrane, the external lipid membrane comprising phospholipids; and The core, which is located inside the outer lipid membrane, The phospholipids of the external lipid membrane are conjugated with a hydrophilic polymer and a targeting portion.
2. The lipid nanoparticles according to claim 1, wherein the hydrophilic polymer is selected from PEG molecules, zwitterionic polymers, or OEGMA.
3. The lipid nanodelivery particles according to claim 1 or 2, wherein the hydrophilic polymer is a PEG molecule.
4. The lipid nanoparticles according to any one of claims 1 to 3, wherein the lipid nanoparticles are selected from the group consisting of: encapsulated nanocomposites (eNCP), lipid nanoparticles (LNP), liposomes, nanocapsules (NC), nanocrystals (NCR), polymer lipid nanoparticles (PLNP), nanoemulsions (NE), and protein lipid carriers (PLV).
5. The lipid nanodelivery particles according to any one of claims 1 to 4, wherein the core is oily or liquid.
6. The lipid nanodelivery particle according to any one of claims 1 to 4, wherein the core is solid.
7. The lipid nanoparticle according to any one of claims 1 to 6, wherein the lipid nanoparticle further comprises an inner lipid membrane comprising phospholipids, wherein the inner lipid membrane is located inside the outer lipid membrane.
8. The lipid nanodelivery particle according to any one of claims 1 to 7, wherein the targeting portion is a peptide, antibody, Fab, scFv, VHH, or organic compound.
9. The lipid nanodelivery particle according to any one of claims 1 to 8, wherein the targeting portion specifically binds to the transferrin receptor (TfR).
10. The lipid nanodelivery particle of claim 9, wherein the targeting portion specifically binding to TfR has an affinity of 0.1 nanomolar to 500 nanomolar.
11. The lipid nanodelivery particle according to any one of claims 1 to 8, wherein the targeting portion specifically binds to a target on peripheral cells.
12. The lipid nanodelivery particle of claim 11, wherein the peripheral cells are T cells.
13. The lipid nanoparticles according to any one of claims 1 to 12, wherein the molecular weight of the hydrophilic polymer is selected from the group consisting of: 1 kDa to 10 kDa; 1 kDa to 5 kDa; and 1 kDa to 3.5 kDa.
14. The lipid nanodelivery particles according to any one of claims 1 to 12, wherein the hydrophilic polymer has a molecular weight of about 2.5 kDa.
15. The lipid nanodelivery particles according to any one of claims 1 to 14, wherein the hydrophilic polymer is a PEG molecule.
16. The lipid nanodelivery particles according to any one of claims 1 to 15, wherein the targeting portion is conjugated with a hydrophilic polymer via a maleimide reaction.
17. The lipid nanodelivery particles according to any one of claims 1 to 15, wherein the targeting portion is conjugated to a hydrophilic polymer via an azide / dibenzocyclooctylene (DBCO) reaction or via an N-hydroxysuccinimide (NHS) / amine reaction.
18. The lipid nanodelivery particle according to any one of claims 1 to 17, wherein about 1% to about 5% molar percentage of the lipid nanodelivery particle is the plurality of phospholipids of the outer lipid membrane to which a hydrophilic polymer is conjugated.
19. The lipid nanodelivery particle according to any one of claims 1 to 18, wherein about 1% to about 2.5% molar percentage of the lipid nanodelivery particle is the plurality of phospholipids of the outer lipid membrane to which the hydrophilic polymer is conjugated.
20. The lipid nanodelivery particle according to any one of claims 1 to 19, wherein about 5% to about 20% of the hydrophilic polymer conjugated to the phospholipids of the outer lipid membrane has a targeting portion conjugated thereto.
21. The lipid nanodelivery particle according to any one of claims 1 to 20, wherein approximately 10% of the hydrophilic polymer conjugated to the phospholipids of the outer lipid membrane has a targeting portion conjugated thereto.
22. The lipid nanodelivery particles according to any one of claims 1 to 21, wherein the targeting portion is conjugated to the hydrophilic polymer via a cleavable linker.
23. The lipid nanodelivery particle according to any one of claims 1 to 22, wherein the core comprises a therapeutic nucleic acid.
24. The lipid nanodelivery particles of claim 23, wherein the therapeutic nucleic acid comprises one or any combination of mRNA, guide RNA (gRNA), microRNA (miRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), interfering RNA (iRNA), antisense oligonucleotide (ASO), Dicer substrate interfering RNA (DsiRNA), miRNA, short hairpin RNA (shRNA), short interfering RNA (siRNA), short activating RNA (saRNA), suppressor tRNA (sup-tRNA), circular RNA (circRNA), and activating RNA (aRNA).
25. A method for targeted delivery of therapeutic nucleic acids to a patient, the method comprising: Therapeutic nucleic acids are encapsulated within the core of lipid nanoparticles according to any one of claims 1 to 22; as well as The lipid nanoparticles containing the therapeutic nucleic acid are administered to the patient.
26. The method of claim 25, wherein the therapeutic nucleic acid comprises one or any combination of mRNA, guide RNA (gRNA), microRNA (miRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), interfering RNA (iRNA), antisense oligonucleotide (ASO), Dicer substrate interfering RNA (DsiRNA), miRNA, short hairpin RNA (shRNA), short interfering RNA (siRNA), short activating RNA (saRNA), suppressor tRNA (sup-tRNA), circular RNA (circRNA), and activating RNA (aRNA).
27. The method according to any one of claims 25 to 26, wherein the administration step comprises any one of intravenous, parenteral, intravenous, intramuscular, intraarterial, intramedullary, intrasheath, intraocular, subcutaneous, intravenous, transdermal, intradermal, rectal, vaginal, intraperitoneal, local, mucosal, nasal, buccal, sublingual, and carotid artery administration.
Citation Information
Patent Citations
School-bag with roller and draw-bar
CN2502549Y
Road Lighting Street Lighting Pole (1)
CN3334662D
cosmetic packaging box
CN3341361D
Transferrin receptor-binding molecules, conjugates thereof and their uses
WO2020144233A1
Transferrin receptor binding proteins
WO2022026555A1
